Compare XBP & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBP | LSTA |
|---|---|---|
| Founded | N/A | 1980 |
| Country | United States | United States |
| Employees | 10200 | N/A |
| Industry | Business Services | Misc Health and Biotechnology Services |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 28.9M |
| IPO Year | N/A | 2000 |
| Metric | XBP | LSTA |
|---|---|---|
| Price | $2.85 | $2.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $15.00 |
| AVG Volume (30 Days) | 10.8K | ★ 26.3K |
| Earning Date | 05-15-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | $2.59 | N/A |
| Revenue Next Year | $5.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $0.41 | $1.81 |
| 52 Week High | $8.55 | $5.07 |
| Indicator | XBP | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 60.37 | 23.92 |
| Support Level | $2.11 | $1.87 |
| Resistance Level | $3.00 | $2.61 |
| Average True Range (ATR) | 0.25 | 0.20 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 57.69 | 13.71 |
XBP Global Holdings Inc is a multinational technology and services company that drives intelligent workflows for organizations. Through its proprietary platforms, agentic AI-driven automation, and domain expertise across industries and the public and private sectors, the firm enables its clients to entrust their digital transformations and workflows. The segments of the company are Applied Workflow Automation and Technology. The Applied Workflow Automation segment generates maximum revenue and provides services powered by intelligent, AI-enabled workflows that generate outcomes for client's systems, while the Technology segment focuses on the sale of recurring and perpetual software licenses, software maintenance and professional services, as well as hardware solutions and maintenance.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.